Tarsons Products Limited Q3 & 9MFY26 Investor Presentation Released
Tarsons Products Limited reported Q3 FY26 consolidated revenue of ₹107.9 crore, up 12.8% YoY, with Adjusted Cash PAT at ₹31.4 crore, up 38.6% YoY. For 9MFY26, consolidated revenue was ₹301.6 crore (up 7.8% YoY) and Adjusted Cash PAT was ₹78.9 crore (up 27.3% YoY). The company is nearing completion of capacity expansion, scheduled for Q4 FY26.
The announcement provides detailed financial results and an update on capacity expansion, which are material for investors. While the growth is positive, the impact on PAT due to depreciation and finance costs for new facilities suggests a cautious outlook for immediate profitability.
The company reported positive year-on-year growth in revenue and Adjusted Cash PAT for both standalone and consolidated results for Q3 and 9MFY26. Management commentary expresses optimism about future growth driven by capacity expansion and new product launches.
Tarsons Products Limited has released its Investor Presentation for the quarter and nine months ended December 31, 2025. The presentation details the financial and operational highlights for both standalone and consolidated results.
For standalone operations in Q3 FY26, revenue grew by 10% year-on-year to ₹84.0 crore, while Adjusted Cash PAT increased by 33.9% to ₹31.1 crore. For the nine months ended FY26, revenue grew 6.6% to ₹235.8 crore, and Adjusted Cash PAT grew 24.5% to ₹79.1 crore. The company noted that PAT was impacted by accelerated depreciation and finance costs related to new facilities at Panchla and Amta.
On a consolidated basis, Q3 FY26 revenue increased by 12.8% to ₹107.9 crore, with Adjusted Cash PAT growing by 38.6% to ₹31.4 crore. For the nine months ended FY26, consolidated revenue grew 7.8% to ₹301.6 crore, and Adjusted Cash PAT grew 27.3% to ₹78.9 crore. A one-time expense of ₹1.3 crore related to the impact of new labor codes was adjusted for in PAT for Q3 & 9MFY26.
Mr. Aryan Sehgal, Promoter and Whole time Director, commented that consolidated revenue for Q3FY26 stood at ₹108 crore, a 12.8% year-on-year growth. EBITDA grew 6.3% YoY to ₹31.5 crore. He attributed the PAT decline to accelerated depreciation and higher finance costs from the new Panchla facility. He expressed optimism about the company's growth trajectory, driven by capacity expansion, an expanded product portfolio, and strong customer relationships, expecting revenue contribution from the new facility in the coming years. The company is in the final phase of capacity expansion, scheduled for commissioning in Q4 FY26.
The presentation also highlighted the company's market position, diversified product portfolio, manufacturing facilities, distribution network, and business strategies, including increasing overseas presence and expanding product offerings.
What to do with a filing like this
Tarsons Products Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tarsons Products Limited. Read the original for the full detail.